|
|
Vaccine Detail
|
Anti-GnRH Vaccine PEP223 |
| Vaccine Information |
- Vaccine Name: Anti-GnRH Vaccine PEP223
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007261
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Gnrh1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: GnRH-DT vaccine con-sists of GnRH linked via a spacer as a hapten to the carrier, diphtheria toxoid (DT), formulated in a water/oil emulsion vehicle (Triozzi et al., 2005).
- Description: A peptide vaccine derived from the synthetic peptide pyroEHWSYGLRPG, corresponding to amino acids 22-31 of mouse gonadotropin releasing hormone (GnRH), with potential immunocastration activity. PEP223 is dimerized and contains a D-lysine (k) substitution at position 6 (pyroEHWSYkLRPG) to increase its immunogenicity. Anti-GnRH vaccine PEP223 may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GnRH, neutralizing its activity. In turn, testosterone production and tumor cell growth may be inhibited in testosterone-sensitive tumors. (NCIT_C85464).
This vaccine was used in clinical trials involving prostate cancer. NCT00895466
|
| Host Response |
|
|
| References |
NCIT_C85464: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85464]
Triozzi et al., 2005: Triozzi PL, Bolger GB, Neidhart J, Rinehart JJ, Saleh M, Allen KO, Sellers S, Waddell MJ. Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer. The Prostate. 2005; 65(4); 316-321. [PubMed: 16015596].
|
|
